Kemudin I.M. (Ceftriaxone)

Ceftriaxone inhibits bacterial cell‑wall synthesis by binding to penicillin‑binding proteins, preventing the cross‑linking of peptidoglycan strands. This weakens the cell wall, causing osmotic rupture and bacterial death. Its high affinity for a broad range of PBPs gives it activity against many gram‑negative and gram‑positive organisms.

The dosage of Kemudin I.M. is individualized by the prescriber according to the infection type, severity, patient age, weight, and renal or hepatic function. Healthcare professionals determine the appropriate amount, frequency, and duration of therapy based on clinical guidelines and laboratory data.

Safety data for ceftriaxone in pregnancy and lactation are limited. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant. The prescribing clinician will assess the risk‑benefit profile before initiating therapy.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity of Kemudin I.M. GNH India works with hospitals, pharmacies, and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details (including cold‑chain where required), and import documentation.

Compared with earlier‑generation cephalosporins, ceftriaxone offers broader gram‑negative coverage, a longer half‑life allowing once‑daily dosing, and good penetration into cerebrospinal fluid, making it advantageous for meningitis. Against carbapenems, it is less potent for multidrug‑resistant organisms but remains a first‑line option for many community‑acquired infections.

Kemudin I.M. should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Before administration, the vial should be inspected for particulate matter and prepared using aseptic technique according to the product’s prescribing information.

Kemudin I.M. is supplied as a sterile powder for injection and is reconstituted with the appropriate diluent. It is administered intramuscularly by a qualified healthcare professional, typically into the gluteal or deltoid muscle, following aseptic preparation and proper injection technique.

Serious risks include severe hypersensitivity reactions such as anaphylaxis, Clostridioides difficile‑associated colitis, Stevens‑Johnson syndrome or toxic epidermal necrolysis, hemolytic anemia, and significant hepatic dysfunction. Patients should be monitored for signs of these reactions, and therapy should be discontinued immediately if they occur.

Kemudin I.M. is contraindicated in individuals with a known hypersensitivity to ceftriaxone, other cephalosporins, or any β‑lactam antibiotics. Neonates ≤28 days old and premature infants should not receive intramuscular injections of this product. Caution is also advised for patients with severe renal or hepatic impairment.